
A biotechnology company that develops and licenses autologous cellular therapies, including Cytomedix's proprietary AutoloGel(tm) Process to produce a platelet rich plasma gel for the treatment of wounds.
The best Bull and Bear pitches based on recency and number of recommendations.
Like many speculative pharma companies Cytomedix smells like a sham to me. On paper the company is worth a whopping $0.145 per share - mostly thanks to a diluting offering of 15.37 million shares since 4Q11 that increased the float by 27.7%!
Read the most recent pitches from players about NUOTQ.
Recs
Untapped market in regenerative wound healing boosted by CMS reimbursement rate decision in late 2013.
Recs
Seems interesting. spec play
Recs
FDA approval. CMS catalysts. Wide open market. This stock is worth more then $114 million.
Find the members with the highest scoring picks in NUOTQ.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
HunterNumber9 | 76.15 | 12/23/2011 |
![]() |
5Y | $1.00 | -98.80% | +233.21% | +332.01 | 0 Comment | |
RAILROADRHETT | < 20 | 10/2/2007 |
![]() |
3W | $5.00 | -99.76% | +184.76% | +284.52 | 0 Comment | |
Crystalball | 49.81 | 4/3/2014 |
![]() |
5Y | $0.54 | -97.79% | +123.09% | -220.88 | 0 Comment | |
Momentum22 | 28.05 | 4/22/2014 |
![]() |
5Y | $0.66 | -98.18% | +123.26% | -221.44 | 0 Comment | |
HoosierDoozer | < 20 | 3/28/2014 |
![]() |
5Y | $0.51 | -97.65% | +125.79% | -223.44 | 0 Comment | |
MusicMoney88 | < 20 | 3/28/2014 |
![]() |
5Y | $0.51 | -97.65% | +127.01% | -224.66 | 0 Comment | |
Zergum | < 20 | 2/18/2014 |
![]() |
5Y | $0.50 | -97.60% | +127.89% | -225.49 | 0 Comment | |
NathanHamilton82 | < 20 | 2/21/2014 |
![]() |
1Y | $0.51 | -97.65% | +127.96% | -225.61 | 1 Comment | |
usainvestmccarty | < 20 | 1/30/2014 |
![]() |
5Y | $0.60 | -98.00% | +134.17% | -232.17 | 0 Comment | |
KidJones | 28.26 | 2/21/2013 |
![]() |
5Y | $0.51 | -97.65% | +178.77% | -276.42 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.